CTMX - Company ID 0001501989
The table below shows CytomX Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$25.55M | -$21.04M | -$26.05M | $9.35M | -$41.31M | -$29.94M |
| Capital expenditure | $0.00 | $119.00K | $115.00K | $48.00K | $736.00K | $982.00K |
| Investing cash flow | -$192.78M | $30.60M | $44.88M | -$146.64M | -$736.00K | $59.01M |
| Dividends paid | - | - | - |
CytomX Therapeutics, Inc. reported operating cash flow of -$75.59M for fiscal year 2025. That is up 12.3% from -$86.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.03M (FY 2016) to -$75.59M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $234.49M | $0.00 | $174.00K | $0.00 | $7.00K | $108.73M |